Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772644 | 0.80 | ERN1 (0.48) | ERN1ALBENPP2 | |
| SCHEMBL2821248 | 0.80 | ERN1 (0.48) | ERN1ALBENPP2 | |
| SCHEMBL7768717 | 0.76 | ALDH1A1 (0.45) | ENPP2 | |
| SCHEMBL5198 | 0.74 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL7772646 | 0.74 | ERN1 (0.40) | ERN1ALB | |
| SCHEMBL29950828 | 0.74 | SCN9A (0.36) | ENPP2 | |
| SCHEMBL7772570 | 0.72 | ENPP2 (0.50) | ERN1ENPP2 | |
| SCHEMBL31546303 | 0.70 | ENPP2 (0.34) | ENPP2 | |
| SCHEMBL29956129 | 0.70 | L3MBTL1 (0.40) | ENPP2 | |
| SCHEMBL3984741 | 0.70 | L3MBTL1 (0.40) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1119573-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6177419-B1 | ANTIOXIDANT CHELATE COMPOUNDS FOR PREVENTING OXYGEN FREE RADICAL-ASSOCIATED DISEASES IN MAMMALS; NEUROPROTECTANTS, SUPEROXIDE DISMUTASE (SOD), CATALASE (CAT) AND/OR PEROXIDASE (POD) MIMETICS | EUKARION, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000009512-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2000-02-24 | — | — | WO | disclosed |